PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
275.14
P/E exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.48. Michael Burry would check for market euphoria. Scrutinize growth expectations.
146.57
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.40. Jim Chanos would check for potential multiple compression risks.
10.78
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.03. Jim Chanos would check for potential asset write-down risks.
-322.31
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
-1022.02
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
10.78
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.08. Jim Chanos would check for valuation bubble risks.
0.09%
Earnings yield near Drug Manufacturers - Specialty & Generic median of 0.09%. Charlie Munger would verify if industry-standard yields make sense.
-0.31%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.